Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Dec 13, 2025, 17:38Amaliris Guerra: Science We Do Has Real Human Stakes
-
Dec 13, 2025, 17:31Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
-
Dec 13, 2025, 17:20James Morrissey Shares the Explanation of A Literally 30 Years Worth of TF Biochemistry
-
Dec 13, 2025, 17:03Danny Hsu: Aspirin May Prevent Cancer Metastases?
-
Dec 13, 2025, 16:33Ana Cláudia de Souza: Opening Event for ÁRTEMIS-Brasil, a PROADI-SUS Project
-
Dec 13, 2025, 16:19Chandra Viswanathan on Altruism and Donating Blood
-
Dec 13, 2025, 16:09Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
-
Dec 13, 2025, 15:36Jeyaraj Pandian’s Visit to China to Support Advancement and Standardization of Stroke Care
-
Dec 13, 2025, 15:20An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!